Tiziana Life Sciences' Semaglutide Combo Shows Potential in Obesity-Related Liver Inflammation

Proactive - Interviews for investors

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to share news the company has announced positive research findings showing the anti-inflammatory potential of the company’s nasal anti-CD3 antibody, foralumab, when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. The study, conducted by Dr. Howard Weiner, Selma Boulenouar, PhD, and their team at Brigham and Women’s Hospital, shows the combination significantly improves liver function and reduces inflammation in diet-induced obesity models. The data reveal that nasal anti-CD3 combined with semaglutide not only promotes liver homeostasis but also markedly decreases pro-inflammatory cytokines, suggesting a promising, multifaceted approach to managing obesity and its challenging complications. These findings underline the potential of this therapy as a breakthrough in addressing both obesity and its often treatment-resistant metabolic effects. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #Ozempic #InflammationResearch #MonoclonalAntibody #BiotechNews #IvorElrifi #ClinicalResearch #SPMS #AlzheimersResearch #GLP1 #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews